An observational study in Miscarriage and Early Pregnancy Loss, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Abortion, Spontaneous with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Abortion, Spontaneous · France.
Among the 27 studies in Abortion, Spontaneous with a site in France, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2022, is one of 13 observational ones, and was the 20th registered.
221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.
Browse Abortion, Spontaneous studies →7 of the 27 studies in Abortion, Spontaneous with a site in France are open now. Recruiting first, the newest first:
Rennes University Hospital · Sites in France
Ages 18–43 · Women only
University Hospital, Toulouse · Sites in France
Ages up to 18 · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–42 · Women only
University Hospital, Brest · Sites in France
Ages 18–40
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 700 is above the median of 201 across 98 observational studies indexed under Abortion, Spontaneous.
Median enrollment 210 across the 14 interventional studies, 202 across the 13 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 5 studies filed under Abortion, Spontaneous — fewer than ten, so there is no comparison to draw.
5 of the studies in Abortion, Spontaneous with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06576622University Hospital, ToulousePERIodontal Disease, Microbiota and Miscarriage | 2026-12-30 |
| NCT07732231Nantes University HospitalCost-utility Analysis of Outpatient Manual Vacuum Aspiration Versus Operating Room Electric Aspiration for the Management of First-trimester Miscarriage | 2027-01-01 |
| NCT06647849University Hospital, AngersInterest of Simulation Training on the Announcement of Early Pregnancy Loss on the Psychological Impact of the Patients | 2027-06-11 |
| NCT05789940University Hospital, MontpellierHysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention | 2027-09-18 |
| NCT05557201Assistance Publique - Hôpitaux de ParisCohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Abortion, Spontaneous with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
About 1 to 3% of women of childbearing age suffer repeated early spontaneous miscarriages (RCF) defined by at least 3 fetal losses before 14 weeks of gestation. RCFs may be linked to parental chromosomal abnormalities, congenital or acquired uterine abnormalities, hormonal causes (e.g. type 1 and 2 diabetes, ovarian failure), infectious etiology, constitutional or acquired thrombophilia or sickle cell disease.
The presence of antiphospholipid antibodies, antithyroid and anti-transglutaminase antibodies in approximately 10% of cases suggests an autoimmune origin for these fetal losses. The role of other antibodies, in particular non-conventional antiphospholipid antibodies, remains to be established. Indeed half of RCF cases are thought to be due to an immunological dysregulation of the mother leading to a decrease in tolerance to the fetus. Several studies have shown immune abnormalities, such as an imbalance of pro and anti-inflammatory cytokines, an increase in cytotoxic cells and a defect in regulatory cells in the blood of patients. The assessment of these immune abnormalities is not currently performed routinely in France in women presenting with recurrent early miscarriages. When one of these known causes is excluded, it is unexplained RCF which represents 50% of RCF. Over half of these women with RCF may be linked to aneuploidies and primary spontaneous recurrent abortions. Assessing the degree of aneuploidy and the genetic origin of foetal losses remains difficult to date, as examination of the miscarriage product is rarely available, due to the spontaneous nature of the loss.
An implantation failure (IF) is defined as the absence of pregnancy following the transfer of a good-quality embryo into the uterine cavity. These implantation failures can be due to embryonic factors, maternal factors, or caused by inappropriate stimulation and/or difficult transfers. In the literature, recurrent implantation failure (RIF) is defined as the absence of pregnancy after 3 attempts of transferring good-quality embryos, taking maternal age into account Setting up a prospective cohort of patients with RFC is an essential step in exploring the aetiological factors of RCF and in order to enable better treatment.
The study population will be followed as part of routine care, in the same way as all patients presenting with RPL, in internal medicine or obstetrics-gynecology.
On the day of inclusion, the patient's medical history will be reviewed (demographic data, lifestyle factors, medical and obstetric-gynecologic history, biological tests performed).
Data for each of the patient's pregnancies will also be collected (date of pregnancy onset, type of pregnancy, pregnancy outcome, treatments taken during pregnancy, maternal/fetal complications during pregnancy).
Patients with recurrent early pregnancy losses (at least 3 fetal losses before 14 weeks of amenorrhea) and/or recurrent implantation failures (at least 3 failures).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with recurrent early pregnancy losses (at least 3 fetal losses before 14 weeks of amenorrhea) and/or recurrent implantation failures (at least 3 failures).
To build a cohort of patients in order to describe clinical characteristics, tests carried out and medical care of patients presenting spontaneous recurrent miscarriages
Description of the clinical and biological characteristics of patients with recurrent early pregnancy losses and/or recurrent implantation failures
Time frame: through study completion, an average of 5 years
To describe the recurrence rate of repeated early pregnancy loss
Proportion of recurrence of early pregnancy loss (EPL) over the entire duration of the study: according to the number of previous early pregnancy losses; according to abnormalities found in the etiological work-up; according to age at onset, associated infertility, type of pregnancy loss with or without live children, and according to the different treatments used
Time frame: Through study completion, an average of 5 years
To describe the recurrence rate of repeated implantation failure
Proportion of recurrence of RIF over the entire duration of the study: according to the number of previous implantation failures, according to abnormalities found in the etiological work-up, according to age at onset, associated infertility, and according to the different treatments used
Time frame: Through study completion, an average of 5 years
To compare the efficacy of immunomodulatory drugs (corticosteroids, hydroxycholoroquin, Intravenous Immunoglobulin Therapy, intralipids, biotherapies)
Description of the efficacy of the various drugs : number of full term pregnancies
Time frame: through study completion, an average of 5 years
To evaluate the psychological state of patients and the impact on pregnancy
Evaluation of the patients' lifestyle using the Baecke questionnaire and medical interrogation.
Time frame: through study completion, an average of 5 years
to evaluate patients' lifestyle and the impact on pregnancy
through study completion, an average of 5 years
Time frame: evaluation of the patients' lifestyle using the Baecke questionnaire and medical interrogation.
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Oct 2027, 60 months after the start.
Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →